Palvella Therapeutics, Inc.
corporate_fare Company Profile
Palvella Therapeutics, Inc. (NASDAQ:PVLA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 36 items for PVLA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-19, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for PVLA spans 8-K, 10-Q.
Recent high-impact activity:
- Palvella Unveils Third QTORIN Program: Topical Docetaxel for EMPD
- Palvella Q3: $236.7M Cash, Net Loss Widens to $24.6M Ahead of Feb 28, 2027 PDUFA
- Palvella Posts $24.6M Q3 Loss, $236.7M Cash Ahead of Feb 2027 PDUFA
- FDA Accepts Palvella's QTORIN Rapamycin NDA, Grants Priority Review; PDUFA Set for Feb 28, 2027
- FDA Accepts NDA, Grants Priority Review for Rare Disease Therapy With Feb 2027 PDUFA
Financial Snapshot
Short Interest & Short Volume
11.46 days to coverFINRA reported short interest of 2,601,661 shares in PVLA as of the October 30, 2026 settlement, a 8.1% increase from the prior period — about 11.5 days to cover at its recent average daily volume. On November 20, 2026, 53.8% of PVLA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.